RELATIVE EFFECTS OF ALPHA(1)-ADRENOCEPTOR BLOCKADE, CONVERTING-ENZYME-INHIBITOR THERAPY, AND ANGIOTENSIN-II SUBTYPE-1 RECEPTOR BLOCKADE ON VENTRICULAR REMODELING IN THE DOG
Km. Mcdonald et al., RELATIVE EFFECTS OF ALPHA(1)-ADRENOCEPTOR BLOCKADE, CONVERTING-ENZYME-INHIBITOR THERAPY, AND ANGIOTENSIN-II SUBTYPE-1 RECEPTOR BLOCKADE ON VENTRICULAR REMODELING IN THE DOG, Circulation, 90(6), 1994, pp. 3034-3046
Background Progressive ventricular remodeling after myocardial damage
is associated with a poor prognosis. Optimal prevention of the histopa
thological processes involved in remodeling requires a more complete u
nderstanding of the mechanisms involved in initiating and maintaining
these structural changes. Since the sympathetic nervous system and the
renin-angiotensin system may be involved in the remodeling process, t
he structural effects of pharmacological inhibitors have been evaluate
d in a canine model of localized myocardial injury resulting from tran
smyocardial DC shock. Methods and Results The study is comprised of tw
o protocols run in series. In protocol 1, zofenopril (Z), a converting
enzyme inhibitor (CEI), prevented the increase in left ventricular ma
ss (LVM) and end-diastolic volume (LVV) observed in the control group
(C) at 16 weeks (Z: LVM, 69.8+/-3.4 to 65.4+/-2.6 g, P=NS; LVV, 45.4+/
-2.7 to 51.6+/-2.7 mL, P=NS; C: LVM, 68.4+/-3.2 to 91.4+/-2.9 g, P=.00
01; LVV, 56.6+/-3.0 to 71.9+/-2.4 mL, P=.0003). Terazosin, an alpha(1)
-adrenoceptor antagonist, failed to prevent remodeling at 16 weeks des
pite continued receptor blockade. In protocol 2, the antiremodeling ef
fect of full-dose CEI therapy with ramipril was confirmed. Low-dose ra
mipril that exerted no hemodynamic effect failed to prevent remodeling
(LVM, 89.7+/-4.6 to 105.7+/-3.4 g, P=.01; LVV, 61.8+/-3.8 to 76.8+/-3
.3 mL, P=.002). An angiotensin II subtype 1 receptor blocker also fail
ed to prevent the increase in LVM or LVV (LVM, 89.0+/-4.6 to 109.7+/-5
.3 g, P=.0001; LVV, 66.0+/-1.9 to 78.4+/-3.6 mL, P=.007). Conclusions
High-dose CEI therapy can prevent progressive structural changes resul
ting from localized myocardial damage induced by DC shock. The failure
of alpha(1)-adrenoceptor blockade and angiotensin II subtype 1 blocka
de to attenuate remodeling argues against an important direct role for
norepinephrine acting through alpha(1)-receptors or angiotensin II ac
ting through the type 1 receptor in the remodeling process in this mod
el.